Kenvue Target of Unusually High Options Trading (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE) saw some unusual options trading on Thursday. Investors bought 37,296 call options on the company. This is an increase of 253% compared to the typical volume of 10,572 call options.

Analyst Ratings Changes

A number of research firms have issued reports on KVUE. Barclays reduced their price objective on Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Monday. UBS Group decreased their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Citigroup increased their price objective on shares of Kenvue from $21.00 to $22.00 and gave the company a “neutral” rating in a research report on Monday. Evercore ISI started coverage on shares of Kenvue in a report on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price on the stock. Finally, Piper Sandler lifted their price target on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $24.42.

Kenvue Stock Up 3.0 %

Shares of NYSE KVUE opened at $23.42 on Friday. The company has a market cap of $44.93 billion, a P/E ratio of 44.19, a PEG ratio of 2.62 and a beta of 1.02. The firm has a 50-day simple moving average of $22.86 and a two-hundred day simple moving average of $22.40. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Research analysts anticipate that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date is Wednesday, May 14th. Kenvue’s payout ratio is presently 154.72%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Bard Financial Services Inc. increased its position in shares of Kenvue by 5.7% during the third quarter. Bard Financial Services Inc. now owns 106,790 shares of the company’s stock worth $2,470,000 after acquiring an additional 5,750 shares during the period. Boyar Asset Management Inc. increased its holdings in Kenvue by 7.2% during the 3rd quarter. Boyar Asset Management Inc. now owns 29,171 shares of the company’s stock worth $675,000 after purchasing an additional 1,948 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Kenvue during the 3rd quarter valued at $1,057,000. Tidal Investments LLC lifted its holdings in shares of Kenvue by 9.9% in the 3rd quarter. Tidal Investments LLC now owns 131,128 shares of the company’s stock worth $3,033,000 after buying an additional 11,849 shares during the period. Finally, Oddo BHF Asset Management Sas purchased a new stake in shares of Kenvue in the 3rd quarter worth $1,570,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.